• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

最小全基因组人 CRISPR-Cas9 文库。

Minimal genome-wide human CRISPR-Cas9 library.

机构信息

Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.

Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.

出版信息

Genome Biol. 2021 Jan 21;22(1):40. doi: 10.1186/s13059-021-02268-4.

DOI:10.1186/s13059-021-02268-4
PMID:33478580
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7818936/
Abstract

CRISPR guide RNA libraries have been iteratively improved to provide increasingly efficient reagents, although their large size is a barrier for many applications. We design an optimised minimal genome-wide human CRISPR-Cas9 library (MinLibCas9) by mining existing large-scale gene loss-of-function datasets, resulting in a greater than 42% reduction in size compared to other CRISPR-Cas9 libraries while preserving assay sensitivity and specificity. MinLibCas9 provides backward compatibility with existing datasets, increases the dynamic range of CRISPR-Cas9 screens and extends their application to complex models and assays.

摘要

CRISPR 引导 RNA 文库已经被反复改进,以提供越来越高效的试剂,尽管它们的大规模是许多应用的障碍。我们通过挖掘现有的大规模基因功能丧失数据集来设计优化的最小全基因组人类 CRISPR-Cas9 文库(MinLibCas9),与其他 CRISPR-Cas9 文库相比,文库大小减少了 42%以上,同时保持了检测的灵敏度和特异性。MinLibCas9 与现有的数据集具有向后兼容性,增加了 CRISPR-Cas9 筛选的动态范围,并将其应用扩展到复杂的模型和检测中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3862/7818936/dba31c25c7f9/13059_2021_2268_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3862/7818936/3e444cd70289/13059_2021_2268_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3862/7818936/dba31c25c7f9/13059_2021_2268_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3862/7818936/3e444cd70289/13059_2021_2268_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3862/7818936/dba31c25c7f9/13059_2021_2268_Fig2_HTML.jpg

相似文献

1
Minimal genome-wide human CRISPR-Cas9 library.最小全基因组人 CRISPR-Cas9 文库。
Genome Biol. 2021 Jan 21;22(1):40. doi: 10.1186/s13059-021-02268-4.
2
A benchmark comparison of CRISPRn guide-RNA design algorithms and generation of small single and dual-targeting libraries to boost screening efficiency.CRISPRn引导RNA设计算法的基准比较以及用于提高筛选效率的小型单靶点和双靶点文库的生成。
BMC Genomics. 2025 Feb 26;26(1):198. doi: 10.1186/s12864-025-11386-3.
3
Reduced gene templates for supervised analysis of scale-limited CRISPR-Cas9 fitness screens.用于监督分析规模受限的 CRISPR-Cas9 适应性筛选的基因模板减少。
Cell Rep. 2022 Jul 26;40(4):111145. doi: 10.1016/j.celrep.2022.111145.
4
SliceIt: A genome-wide resource and visualization tool to design CRISPR/Cas9 screens for editing protein-RNA interaction sites in the human genome.SliceIt:一个全基因组资源和可视化工具,用于设计 CRISPR/Cas9 筛选,以编辑人类基因组中蛋白质-RNA 相互作用位点。
Methods. 2020 Jun 1;178:104-113. doi: 10.1016/j.ymeth.2019.09.004. Epub 2019 Sep 5.
5
Guide RNA Design for Genome-Wide CRISPR Screens in Yarrowia lipolytica.在解脂耶氏酵母中进行全基因组 CRISPR 筛选的向导 RNA 设计。
Methods Mol Biol. 2021;2307:123-137. doi: 10.1007/978-1-0716-1414-3_8.
6
Practical Considerations for Using Pooled Lentiviral CRISPR Libraries.使用混合慢病毒CRISPR文库的实际考量
Curr Protoc Mol Biol. 2016 Jul 1;115:31.5.1-31.5.13. doi: 10.1002/cpmb.8.
7
Generation of an arrayed CRISPR-Cas9 library targeting epigenetic regulators: from high-content screens to in vivo assays.靶向表观遗传调控因子的 CRISPR-Cas9 文库的构建:从高通量筛选到体内测定。
Epigenetics. 2017;12(12):1065-1075. doi: 10.1080/15592294.2017.1395121. Epub 2018 Jan 12.
8
PINCER: improved CRISPR/Cas9 screening by efficient cleavage at conserved residues.PINCER:通过在保守残基处的有效切割提高 CRISPR/Cas9 筛选效率。
Nucleic Acids Res. 2020 Sep 25;48(17):9462-9477. doi: 10.1093/nar/gkaa645.
9
Optimized minimal genome-wide human sgRNA library.优化后的全基因组最小人类 sgRNA 文库。
Sci Rep. 2023 Jul 18;13(1):11569. doi: 10.1038/s41598-023-38810-6.
10
Evaluation and Design of Genome-Wide CRISPR/SpCas9 Knockout Screens.全基因组CRISPR/SpCas9基因敲除筛选的评估与设计
G3 (Bethesda). 2017 Aug 7;7(8):2719-2727. doi: 10.1534/g3.117.041277.

引用本文的文献

1
Revealing genetic drivers of ovarian cancer and chemoresistance: insights from whole-genome CRISPR-knockout library screens.揭示卵巢癌及化疗耐药的遗传驱动因素:来自全基因组CRISPR敲除文库筛选的见解
Cell Oncol (Dordr). 2025 Aug 28. doi: 10.1007/s13402-025-01102-4.
2
CRISPR/Cas9-based discovery of ccRCC therapeutic opportunities through molecular mechanism and immune microenvironment analysis.通过分子机制和免疫微环境分析,基于CRISPR/Cas9发现肾透明细胞癌的治疗机会
Front Immunol. 2025 Jul 10;16:1619361. doi: 10.3389/fimmu.2025.1619361. eCollection 2025.
3
CRISPR screening approaches in breast cancer research.

本文引用的文献

1
Genome-scale CRISPR screening at high sensitivity with an empirically designed sgRNA library.基于经验设计的 sgRNA 文库的高灵敏度全基因组 CRISPR 筛选。
BMC Biol. 2020 Nov 23;18(1):174. doi: 10.1186/s12915-020-00905-1.
2
Optimization of AsCas12a for combinatorial genetic screens in human cells.优化 AsCas12a 以用于人类细胞中的组合遗传筛选。
Nat Biotechnol. 2021 Jan;39(1):94-104. doi: 10.1038/s41587-020-0600-6. Epub 2020 Jul 13.
3
Genetic screens in isogenic mammalian cell lines without single cell cloning.在同基因的哺乳动物细胞系中进行遗传筛选,无需单细胞克隆。
乳腺癌研究中的CRISPR筛选方法。
Cancer Metastasis Rev. 2025 Jul 12;44(3):59. doi: 10.1007/s10555-025-10275-1.
4
The synthetic lethal interaction between CDS1 and CDS2 is a vulnerability in uveal melanoma and across multiple tumor types.CDS1和CDS2之间的合成致死相互作用是葡萄膜黑色素瘤以及多种肿瘤类型中的一个脆弱点。
Nat Genet. 2025 Jul 4. doi: 10.1038/s41588-025-02222-1.
5
CRISPR GENome and epigenome engineering improves loss-of-function genetic-screening approaches.CRISPR基因组和表观基因组工程改进了功能丧失型基因筛选方法。
Cell Rep Methods. 2025 Jun 16;5(6):101078. doi: 10.1016/j.crmeth.2025.101078. Epub 2025 Jun 10.
6
BRCA1-A and LIG4 complexes mediate ecDNA biogenesis and cancer drug resistance.BRCA1-A和LIG4复合物介导染色体外环状DNA的生物发生及癌症耐药性。
bioRxiv. 2025 Feb 23:2025.02.18.638901. doi: 10.1101/2025.02.18.638901.
7
Genome-wide CRISPR guide RNA design and specificity analysis with GuideScan2.使用GuideScan2进行全基因组CRISPR引导RNA设计和特异性分析。
Genome Biol. 2025 Feb 26;26(1):41. doi: 10.1186/s13059-025-03488-8.
8
A benchmark comparison of CRISPRn guide-RNA design algorithms and generation of small single and dual-targeting libraries to boost screening efficiency.CRISPRn引导RNA设计算法的基准比较以及用于提高筛选效率的小型单靶点和双靶点文库的生成。
BMC Genomics. 2025 Feb 26;26(1):198. doi: 10.1186/s12864-025-11386-3.
9
A roadmap toward genome-wide CRISPR screening throughout the organism.在整个生物体中进行全基因组CRISPR筛选的路线图。
Cell Genom. 2025 Mar 12;5(3):100777. doi: 10.1016/j.xgen.2025.100777. Epub 2025 Feb 24.
10
Synthetic lethal strategies for the development of cancer therapeutics.用于癌症治疗开发的合成致死策略。
Nat Rev Clin Oncol. 2025 Jan;22(1):46-64. doi: 10.1038/s41571-024-00966-z. Epub 2024 Dec 3.
Nat Commun. 2020 Feb 6;11(1):752. doi: 10.1038/s41467-020-14620-6.
4
Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets.两项大型泛癌 CRISPR-Cas9 基因依赖性数据集中的一致性。
Nat Commun. 2019 Dec 20;10(1):5817. doi: 10.1038/s41467-019-13805-y.
5
Pooled library screening with multiplexed Cpf1 library.多重 Cpf1 文库的 pooled library screening。
Nat Commun. 2019 Jul 17;10(1):3144. doi: 10.1038/s41467-019-10963-x.
6
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.利用 CRISPR-Cas9 筛选技术对癌症治疗靶点进行优先级排序。
Nature. 2019 Apr;568(7753):511-516. doi: 10.1038/s41586-019-1103-9. Epub 2019 Apr 10.
7
Structural rearrangements generate cell-specific, gene-independent CRISPR-Cas9 loss of fitness effects.结构重排产生细胞特异性、基因独立性的 CRISPR-Cas9 适应性丧失效应。
Genome Biol. 2019 Feb 5;20(1):27. doi: 10.1186/s13059-019-1637-z.
8
JACKS: joint analysis of CRISPR/Cas9 knockout screens.JACKS:CRISPR/Cas9 敲除筛选的联合分析。
Genome Res. 2019 Mar;29(3):464-471. doi: 10.1101/gr.238923.118. Epub 2019 Jan 23.
9
Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities.具有多种模式的 CRISPR-Cas9 基因筛选的优化文库。
Nat Commun. 2018 Dec 21;9(1):5416. doi: 10.1038/s41467-018-07901-8.
10
Predicting the mutations generated by repair of Cas9-induced double-strand breaks.预测由Cas9诱导的双链断裂修复所产生的突变。
Nat Biotechnol. 2018 Nov 27. doi: 10.1038/nbt.4317.